Guggenheim analyst Subbu Nambi initiated coverage of Guardant Health with a Neutral rating and no price target. The analyst initiated coverage on nine select specialty tools and specialty diagnostic lab companies. The life sciences tools group remains a large and growing industry where innovation expands applications and opens up new markets, the analyst tells investors in a research note. The firm says that over time, these applications can enable the development of disruptive therapies. Guggenheim’s top picks are Illumina (ILMN), Natera (NTRA) and Exact Sciences (EXAS).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GH:
- Guardant Health initiated with neutral view at Wolfe Research, here’s why
- Guardant Health initiated with neutral view at Wolfe Research
- Guardant Health, Cancer Research Horizons collaborate to advance cancer research
- Guardant Health to appeal intellectual property federal district court verdict
- Guardant Health upgraded to Outperform from Market Perform at Raymond James
